Fragment based inhibitor discovery of the MEP pathway in infectious organisms.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI093060-01
Agency Tracking Number: R43AI093060
Amount: $99,974.00
Phase: Phase I
Program: SBIR
Awards Year: 2011
Solicitation Year: 2011
Solicitation Topic Code: NIAID
Solicitation Number: PA10-050
Small Business Information
EMERALD BIOSTRUCTURES
7869 NE DAY RD W, BAINBRIDGE ISLAND, WA, 98110-
DUNS: 16974144
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 BART STAKER
 (206) 780-8912
 bstaker@embios.com
Business Contact
 BART STAKER
Phone: (206) 780-8912
Email: bstaker@embios.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): We will apply nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography to study enzymes from the methyl erythritol isoprenoid (MEP) biosynthetic pathway, which is essential in multiple pathogens and absent in humans. Identification and biophysical characterization of fragments which bind to MEP targets will generate data for the rational design of small molecule leads for MEP enzymatic inhibition. Through iterative synthesis and structure determination, wewill develop these leads into novel compounds capable of binding MEP enzymes from a variety of infectious disease organisms. Success in this endeavor would lead to a Phase II proposal for focused synthesis and in vitro/in vivo potency testing to prove efficacy and advance these compounds closer to the clinic. The ultimate goal of this project is the development of novel treatments for those infected with drug-resistant strains of malaria, tuberculosis, and other microbial infections, as there are currentlyno MEP pathway inhibitor combination therapies approved for clinical usage PUBLIC HEALTH RELEVANCE: This project proposes to utilize biophysical methods to discover lead compounds that bind to enzymes from the methyl erythritol isoprenoid (MEP) biosynthetic pathway. The ultimate goal of this project is the development of novel treatments for those infected with drug-resistant strains of malaria, tuberculosis, and other microbial infections, as there are currently no MEP pathway inhibitor combinationtherapies approved for clinical usage.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government